Fostair NEXThaler: extrafine dry powder inhaler launched for asthma

Fostair NEXThaler (formoterol/beclometasone) is the first dry powder inhaler delivering extrafine drug particles to be launched in the UK.

Fostair NEXThaler (formoterol/beclometasone) is licensed for the regular treatment of adults with asthma.
Fostair NEXThaler (formoterol/beclometasone) is licensed for the regular treatment of adults with asthma.

Fostair NEXThaler contains the long-acting beta2 agonist, formoterol, and the corticosteroid, beclometasone. The NEXThaler device is a breath-actuated dry powder inhaler which delivers the combination of drugs as extrafine particles to improve lung deposition and allowing a lower dose of corticosteroid to be given. 

The manufacturer states that the device has been developed to be "intuitive to use" and utilises a dose counter that only decreases when a dose has been correctly inhaled (compared with existing dose counters that decrease when a dose has been primed or loaded), with the aim of "accurately tracking adherence".

Prescribers should note that the beclometasone doses in Fostair products are not equivalent to those delivered by non-extrafine formulations. Owing to the difference in particle sizes, 250 microgram beclometasone administered via a standard inhaler is therapeutically equivalent to 100 microgram beclometasone in a Fostair product when given via the new NEXThaler device or the pre-existing pressurised metered dose inhaler (pMDI).

The efficacy and safety of formoterol and beclometasone for the treatment of asthma is well established. The Fostair NEXTinhaler device was compared with the Fostair pMDI in an 8-week randomised, double-blind, four-arm parallel-group study (NEPTUNE) in 754 adults with controlled asthma. Investigators found the NEXThaler device to be non-inferior to the existing pMDI in terms of change from baseline in average pre-dose morning peak expiratory flow.

View Fostair drug record

Further information: Chiesi

Follow MIMS on Twitter


Read these next

Sirdupla: new LABA/corticosteroid inhaler

Sirdupla: new LABA/corticosteroid inhaler

Sirdupla (salmeterol/fluticasone) has been launched...

DuoResp Spiromax: new formoterol/budesonide inhaler

DuoResp Spiromax: new formoterol/budesonide inhaler

DuoResp Spiromax (formoterol/budesonide) has been launched...

New COPD licence for Fostair

New COPD licence for Fostair

Fostair (formoterol/beclometasone) can now be prescribed...

Relvar Ellipta: combination inhaler for asthma and COPD

Relvar Ellipta: combination inhaler for asthma and COPD

Relvar Ellipta (vilanterol/fluticasone furoate) is...

Fostair now for maintenance and reliever therapy in asthma

Fostair now for maintenance and reliever therapy in asthma

Fostair (formoterol/beclometasone) can now be prescribed...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.